HDLBP

Across TCGA pan-cancer cohorts, HDLBP Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated HDLBP data layer compared with 27 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher HDLBP Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated HDLBP expression acts as an unfavorable survival marker, although some lineages such as UCEC and BLCA show a favorable association.

BRCA, UCEC, and LUAD are the cancer types where HDLBP Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	OS	Median	III,IV	0.140	0.833	<.001	24	view →
UCEC	OS	Median	All	0.834	0.657	.011	24	view →
LUAD	DFS	Median	All	0.206	0.767	.006	9	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
LUSC	OS	Median	All	0.173	0.724	.046	3	view →
BLCA	DFS	Median	III,IV	1.000	0.181	.047	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

HDLBP–BRCA (OS)

Open the BRCA breakdown →